Neurocrine Biosciences (0K6R.L) Stock Price

Financial Performance

Neurocrine Biosciences has shown a steady growth in revenue, with last quarter's revenue of $627.7M marking a rise of 0.9% from the previous quarter and an impressive increase of 21.8% year over year. The gross profit also followed a similar pattern, standing at $618.4M, which is up by 0.7% from the previous quarter and up by 23.1% from the previous year. However, their operating income profit was down by -22.7% from the previous quarter to $142M indicating some operational challenges or increased expenses.

Stock Price & Technical Analysis

The stock price currently stands at $118, showing an upward trend over the last month with a gain of 24.2%. However, it shows a decrease when looked at on a yearly basis with -14%. The RSI value being above 70 indicates that the stock might be in overbought territory while its PE ratio stands relatively high at around 161 which might suggest that investors are expecting high future earnings growth.

Alternative Data Signals

The company's web traffic seems to have decreased significantly both month-over-month and year-over-year which could indicate less interest or activity related to the company online but this does not necessarily translate into poor financial performance or outlook for the stock itself as it can be influenced by various factors such as marketing efforts etc.

The number of job openings has slightly decreased which may suggest slower expansion but this is balanced out by very positive employee sentiment about business outlook (94%). Social media following has been increasing rapidly especially on Facebook where they saw an increase in followers by approximately two-thirds within just three months.

Conclusion

In conclusion, Neurocrine Biosciences' stock performance can be considered to be neutral to slightly bullish. The company's financials show a positive trend in terms of revenue and gross profit, despite a recent drop in operating income. The stock price has been increasing recently but its high PE ratio might suggest overvaluation while the RSI indicates it may currently be overbought.

Note: This AI Stock Analysis is based on data as of May 10. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Neurocrine Biosciences (0K6R.L), currently trading at $121.1, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.